Rodent-Based Platforms for Translational Ophthalmology Research
Ocular Disease Models
Key Features of Our Ophthalmology Platform
Rodent models play an essential role in ophthalmic drug discovery, offering reliable systems for studying human eye diseases across both the anterior and posterior segments. With their genetic versatility, surgical adaptability, and well-established protocols, mice and rats are the ideal choice for replicating the pathological hallmarks of ocular disorders.
At Medicilon, our ocular disease platform integrates validated rodent models to evaluate disease mechanisms, drug efficacy, and delivery strategies, supporting therapeutic development from early discovery to IND-enabling studies.
Human Disease Relevance
Our models replicate the key pathological features of human eye diseases, ensuring translational alignment across preclinical stages.
Validated Endpoints & Readouts
We offer a range of validated assessments:
- Tear volume measurement
- Fluorescein staining
- Histopathology
- Retinal angiography
Rodent Specialization
Using mice and rats, our models are genetically flexible, and suitable for surgical or chemical induction.
Versatile Dosing Routes
Study designs include topical, systemic, and intravitreal delivery, tailored to your therapeutic goals.
Custom Study Execution
We offer adaptable protocols that match your research timelines, from early-phase screening to regulatory-ready IND studies.
Extensive Ocular Disease Models
Medicilon’s ocular disease platform integrates validated rodent models to evaluate disease mechanisms and supporting your next therapeutic development.
Ocular Disease Models
Disease Type
- Dry Eye Disease (DED)
- Conjunctival Tissue Proliferation & NV
- Diabetic Retinopathy (DR)
- Choroidal Neovascularization (CNV) & Subretinal Fibrosis
- Corneal neovascularization (Corneal NV)
- Retinal neovascularization
- Acute ocular inflammation models
Partner with Medicilon for Ophthalmic Innovation
Whether you’re developing treatments for dry eye disease, retinal degeneration, or neovascular disorders, Medicilon delivers the scientific rigor and translational power needed to move your ophthalmology pipeline forward.
Tumor Models
Non-tumor Models
cancer therapy INNOVATION
Beyond Orthotopic Models, A Full-Spectrum Oncology Research Suite
Tumor models:
Medicilon provides a comprehensive range of oncology models, including:
- CDX Models – Fast, reliable tumor models for early-phase drug screening.
- PDX Models – Clinically relevant models for personalized medicine research.
- Syngeneic Mouse Models – Immunocompetent tumor models for evaluating novel cancer therapies in a controlled setting.
- Humanized Mouse Models – Bridge the gap between preclinical and clinical immunotherapy studies.
This holistic approach ensures that researchers can seamlessly transition from early drug discovery to translational research, accelerating the path to clinical trials.
In Vitro Assays for Early Stage Discovery
Complementing our in vivo models, Medicilon offers predictive in vitro systems that bridge bench-to-bedside.
With deep expertise in custom assay development, we work closely with clients to design solutions that align with their mechanism of action, disease biology, and development goals.
- Target Discovery & Validation:
- Using CRISPR, RNAi, and gene editing in human or rodent cell models.
- High-Throughput Phenotypic Assays:
- Including high-content imaging, bioenergetics profiling, and Seahorse analysis.
- Screening Across Modalities:
- Supporting small molecules, biologics, peptides, oligonucleotides, and mRNA therapeutics.
- Biomarker Discovery:
- Employing omics technologies such as metabolomics, lipidomics, and proteomics for translational insights.
